Heier Jeffrey S. 4

What Happened
Jeffrey S. Heier, Chief Scientific Officer of Ocular Therapeutix, sold 3,018 shares of company common stock in an open-market disposition on May 26, 2026. The weighted-average price was $8.20 per share for total proceeds of about $24,748. This sale was a sell-to-cover tied to RSU tax withholding and was not a discretionary trade by the reporting person.

Key Details

• Transaction date: 2026-05-26 (reported on Form 4 filed 2026-05-28). Filing appears timely.
• Price: weighted average $8.20; individual sale prices ranged $8.1529–$8.2509.
• Shares sold: 3,018; proceeds ≈ $24,748.
• Reason/footnote: Sold pursuant to a durable automatic sale instruction (adopted Apr 9, 2024) to effect a sell-to-cover election for tax withholding tied to RSUs that vested May 22, 2026. The filing states these sales were not discretionary.
• Additional note: The filer will provide a breakdown of the number of shares sold at each price on request (per the footnote).
• Shares owned after the transaction: not specified in the information provided.

Context
This was a routine, non-discretionary sell-to-cover to satisfy tax withholding on vested restricted stock units—not an indicated investment view. Such transactions are common when RSUs vest and do not necessarily signal insider sentiment about the company's prospects.